Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment

Abstract

These data show that treatment with bortezomib leads to enhanced markers of osteoblast activity in patients with myeloma. The comparison with the control group suggests that the effect on osteoblasts is unique to the proteasome inhibitor.